Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;39(7):683-690.
doi: 10.1007/s40261-019-00794-5.

Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors

Michael Limenta  1 , Christine S C Ho  2 , Jalene W W Poh  2 , Su-Yen Goh  3 , Dorothy S L Toh  2
Affiliations

Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors

Michael Limenta et al. Clin Drug Investig. 2019 Jul.

Abstract

BACKGROUND AND OBJECTIVE: As of December 2017, 20 diabetic ketosis (DK)/diabetic ketoacidosis (DKA) cases associated with sodium-glucose co-transporter 2 inhibitors (SGLT2i) had been reported to the Health Sciences Authority (HSA), Singapore. We aimed to provide a detailed analysis of the profile of these cases.

Methods: As part of the emerging safety issue monitoring, the HSA followed up on SGLT2i-associated DK/DKA cases with the reporters to obtain the missing and/or supplementary information. Descriptive statistics were employed to summarise the data collected, while the Mann-Whitney test was employed to evaluate the differences between typical and euglycaemic DKA cases as well as between genders.

Results: All cases led to hospitalisation but were non-fatal. Where reported, the majority (71-85%) of DK/DKA cases occurred within 180 days of SGLT2i therapy initiation and involved female patients and/or patients with long-standing type 2 diabetes mellitus (T2DM). Apart from the difference in blood glucose levels, no differences in the profile between the typical and euglycaemic DKA cases were noted. Known precipitating factors were identified in all cases. Acute illnesses, particularly infections and abscesses, were the most commonly reported precipitating factors, followed by insulin dose reduction/cessation.

Conclusions: Based on the profile of the reported cases, it is imperative to maintain clinical vigilance for DK/DKA, especially during the first 6 months of SGLT2i treatment and more so in female patients and/or patients with long-standing T2DM. Prompt evaluation and management of underlying precipitating factors is also important to assess and mitigate the risk of developing DK/DKA during treatment with SGLT2i.

PubMed Disclaimer

Conflict of interest statement

Michael Limenta, Christine S. C. Ho, Jalene W. W. Poh, Su-Yen Goh and Dorothy S. L. Toh have no conflicts of interest that are directly relevant to the content of this article. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the Health Sciences Authority or any of its committees or working parties.

Figures

Fig. 1
Fig. 1
Time from sodium–glucose co-transporter 2 inhibitor (SGLT2i) treatment initiation to DK/DKA onset. DK diabetic ketosis, DKA diabetic ketoacidosis
Fig. 2
Fig. 2
Frequency of the identified precipitants of DK/DKA. DK diabetic ketosis, DKA diabetic ketoacidosis, BMI body mass index
Fig. 3
Fig. 3
Sodium–glucose co-transporter 2 inhibitor (SGLT2i) exposure and reporting rate of SGLT2i-associated DK/DKA. DK diabetic ketosis, DKA diabetic ketoacidosis, DDD defined daily dose
See this image and copyright information in PMC

References

    1. Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559. doi: 10.1038/nrd3180. - DOI - PubMed
    1. De P, Child DF. Euglycaemic diabetic ketoacidosis—is it on the rise? Pract Diabetes Int. 2001;18:239–240. doi: 10.1002/pdi.245. - DOI
    1. Rjf E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–1642. doi: 10.2337/dc15-1380. - DOI - PubMed
    1. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512–517. doi: 10.1038/nm.3828. - DOI - PubMed
    1. Kitabchi AE, Hirsch IB, Emmet M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: clinical features, evaluation, and diagnosis. In: Post TW, editor. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults. Waltham: UpToDate; 2018.